AI assistant
IMPEDIMED LIMITED — Board/Management Information 2020
May 4, 2020
65135_rns_2020-05-04_64fba172-f618-4b6b-9008-c13b861f1202.pdf
Board/Management Information
Open in viewerOpens in your device viewer
5 May 2020
==> picture [230 x 55] intentionally omitted <==
ASX ANNOUNCEMENT
US INSURANCE INDUSTRY EXPERT JOINS BOARD OF DIRECTORS
Brisbane, Australia – ImpediMed Limited (ASX.IPD), a medical software technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscopy (BIS), is today pleased to announce the appointment of David W. Anderson as a Non-Executive Director.
Mr. Anderson currently serves as President and CEO of HealthNow Systems Inc, operating as Blue Cross Blue Shield health plans in New York State. Additionally, HealthNow Systems provides other health care administrative services in New York, Pennsylvania and California. HealthNow operates as a licensee of the Blue Cross Blue Shield Association, which in total, provides health care services to 1 in every 3 Americans across all 50 states and US territories. Trusted for over 80 years, BCBS is accepted at over 90% of US doctors, hospitals and other health care providers.
Mr. Anderson is a very experienced and respected US health care industry executive who serves on the board of the National Institute of Healthcare Management, Blue Cross Blue Shield Association board of Directors, the board of the New York State Business Council and the New York State Insurance Advisory Committee as appointed by the Commissioner of the Department of Financial Services. Additionally, Mr Anderson serves as an advisor and speaker for Modern Healthcare’s CEO Power Panel and the Aspen Institute. Prior to his role at BCBS, Mr. Anderson was CEO of United Healthcare’s Southern California Health Plan.
“We are very excited to welcome a Director of David’s calibre and experience to ImpediMed’s Board,” said Scott Ward, Non-executive Chairman of ImpediMed. “David is a seasoned health insurance executive and brings a deep understanding of the health insurance providers in the United States. We anticipate David’s experience will be invaluable in helping guide ImpediMed through commercialisation of its SOZO[®] Digital Health Platform.”
Authorised for release by the Board of Directors of ImpediMed Limited.
Contact Details
Investor Relations Contact: Media Contact: Mike Bassett, ImpediMed Kyahn Williamson, WE Buchan T : +61 407 431 432 T: +61 3 9866 4722 E: [email protected] E: [email protected]
About ImpediMed
Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical software technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscopy (BIS).
ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO[®] for multiple indications including heart failure, protein calorie malnutrition and lymphoedema, sold in select markets globally.
For more information, visit www.impedimed.com.
1